Mesoporous silica nanocarriers encapsulated antimalarials with high therapeutic performance

• Published in: Scientific reports Vol. 8; no. 1; pp. 3078 - 9
• Main Authors: Amolegbe, Saliu Alao, Hirano, Yui, Adebayo, Joseph Oluwatope, Ademowo, Olusegun George, Balogun, Elizabeth Abidemi, Obaleye, Joshua Ayoola, Krettli, Antoniana Ursine, Yu, Chengzhong, Hayami, Shinya
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 15.02.2018; Nature Publishing Group
• Subjects: 631/154/152; 639/925/352/152; 64/60; Antimalarial activity; Antimalarial agents; Antimalarials - administration & dosage; Antimalarials - pharmacology; Biomaterials; Biomedical materials; Body weight; Cytotoxicity; Drug delivery; Drug Delivery Systems - methods; Drug development; Erythrocytes - drug effects; Humanities and Social Sciences; Inhibitory Concentration 50; Malaria - drug therapy; multidisciplinary; Nanoparticles - chemistry; Plasmodium berghei - drug effects; Plasmodium falciparum - drug effects; Quinine; Quinine - pharmacology; Science; Science (multidisciplinary); Silica; Silicon Dioxide - pharmacology
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-018-21351-8

The use of nanocarriers in drug delivery is a breakeven research and has received a clarion call in biomedicine globally. Herein, two newly nano-biomaterials: MCM-41 encapsulated quinine (MCM-41 ⊃ QN) ( 1 ) and 3-phenylpropyl silane functionalized MCM-41 loaded QN (pMCM-41 ⊃ QN) ( 2 ) were synthesized and well characterized. 1 and 2 along with our two already reported nano-antimalarial drugs (MCM-41 ⊃ ATS) ( 3 ) and 3-aminopropyl silane functionalized MCM-41 contained ATS (aMCM-41 ⊃ ATS) ( 4 ) were screened in vitro for their activity against P. falciparium W2 strain, cytotoxicity against BGM cells and in vivo for their activity against Plasmodium bergheiNK65 . 1 has the highest antimalarial activity in vivo against P. berghei NK65, (ED 50 : < 0.0625 mg/kg body weight) and higher mean survival time compared to the other nano biomaterials or unencapsulated drugs at doses higher than 0.0625 mg/kg body weight. This encapsulation strategy of MCM-41 ⊃ QN ( 1 ) stands very useful and effective in delivering the drug to the target cells compared to other delivery systems and therefore, this encapsulated drug may be considered for rational drug design.